NCT05219578 is a Phase 1, PHASE2 clinical trial of RTX-224 in Non Small Cell Lung Cancer, sponsored by Rubius Therapeutics.

Who is sponsoring NCT05219578?

NCT05219578 is sponsored by Rubius Therapeutics.

What drugs are being tested in NCT05219578?

Interventions in NCT05219578: RTX-224.

What condition does NCT05219578 study?

NCT05219578 studies Non Small Cell Lung Cancer, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma, TNBC - Triple-Negative Breast Cancer.

Is NCT05219578 still recruiting?

NCT05219578 is currently terminated. Last updated 9 December 2022.

Last reviewed 2022-12-09 · How we verify

NCT05219578

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RTX-224 Monotherapy in Patients With Solid Tumors

Terminated Phase 1, PHASE2 Last updated 9 December 2022

What this trial tests

Phase 1, PHASE2 trial testing RTX-224 in Non Small Cell Lung Cancer in 7 participants. Terminated before completion.

Timeline

12 January 2022

Primary endpoint
30 November 2022

30 November 2022

Quick facts

Lead sponsor	Rubius Therapeutics
Phase	Phase 1, PHASE2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	7
Start date	12 January 2022
Primary completion	30 November 2022
Estimated completion	30 November 2022
Sites	5 locations across United States

Drugs / interventions tested

RTX-224 — full drug profile →

Conditions studied

Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →
Cutaneous Melanoma — all drugs for Cutaneous Melanoma →
Head and Neck Squamous Cell Carcinoma — all drugs for Head and Neck Squamous Cell Carcinoma →
Urothelial Carcinoma — all drugs for Urothelial Carcinoma →

Sponsor

Rubius Therapeutics — full company profile →

Who can join

18 and older, any sex, with Non Small Cell Lung Cancer or Cutaneous Melanoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label, multidose, first-in-human (FIH), Phase 1/2 study of RTX-224 for the treatment of patients with relapsed or refractory (R/R), or locally advanced solid tumors.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Cell-drug conjugates.
Wang Y, Shi J, Xin M, Kahkoska AR, et al · · 2024 · cited 29× · PMID 38951139 · DOI 10.1038/s41551-024-01230-6
Red blood cells in biology and translational medicine: natural vehicle inspires new biomedical applications.
Zhang X, Lin Y, Xin J, Zhang Y, et al · · 2024 · cited 22× · PMID 38164142 · DOI 10.7150/thno.87425
Theoretical basis, state and challenges of living cell-based drug delivery systems.
Liu W, Cheng G, Cui H, Tian Z, et al · · 2024 · cited 11× · PMID 39267776 · DOI 10.7150/thno.99257
Cell-drug conjugates: a novel drug delivery system for cancer therapy.
Cheng X, He M, Zeng Y, Li A, et al · · 2026 · PMID 41993617 · DOI 10.7150/thno.127171

Verify or expand the search:

Other recruiting trials for Non Small Cell Lung Cancer

Currently open trials in the same condition.

NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07269782 — A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCL · Phase 2 · recruiting
NCT07306624 — Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer · Phase 2 · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting

Other Rubius Therapeutics trials

Trials by the same sponsor.

NCT04672980 — RTX-321 Monotherapy in Patients With HPV 16+ Tumors · Phase 1 · terminated
NCT04372706 — RTX-240 Monotherapy and in Combination With Pembrolizumab · Phase 1, PHASE2 · terminated
NCT04110496 — Safety and Tolerability of RTX-134 in Adults With Phenylketonuria · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05219578 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rubius Therapeutics
Last refreshed: 9 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05219578.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing